Jason Napodano | TalkMarkets | Page 2

Articles

Latest Posts
17 to 32 of 54 Posts
<<< 1 2 3 4 >>>
MAT2501 Phase 1 Data Look Good, Shares Look Attractive
Wednesday, March 29, 2017 10:09 AM EDT
Matinas Biopharma's stock is cheap and I can easily see Matinas getting taken out at much higher levels - like most anti-infectant companies do - perhaps after the pipeline matures a bit.
In this article: MTNB
Read
Why I'm Long Shares Of HedgePath Pharma
Wednesday, March 22, 2017 12:44 PM EDT
HedgePath remains an attractive story for small-cap biotech investors. The company is likely to report positive top-line Phase 2b results during the first half of 2017.
In this article: HPPI
Read
EMA Gives Thumbs-Up To Actinium's Phase 3 SIERRA Program
Tuesday, March 21, 2017 10:07 AM EDT
Today's news is very positive for Actinium. Enrollment in SIERRA continues on plan and there are DMC updates expected around the middle of the year and again potentially at year end.
In this article: ATNM
Read
BioSig Secures Cash, Prepares For PURE EP 510(k) Application
Friday, March 17, 2017 12:57 AM EDT
Over the past month, BioSig Technologies, Inc. raised roughly $1.5 million in cash through the sale of nearly one million shares of common stock to accredited investors, which included participation from management, at $1.50 per share.
In this article: BSGM
Read
BriaCell Phase 1/2a Trial Underway
Thursday, March 16, 2017 5:30 AM EDT
BriaCell Therapeutics remains one of my favorite under-the-radar immuno-oncology names. Finally, the CEO just invested $1.5 million of his own money into the story and that alone should warrant investors attention.
In this article: BCTXW
Read
BrainStorm Strengthens Management Team, Expands Board
Monday, March 6, 2017 3:12 PM EDT
BrainStorm’s next step in the development of NurOwn is to initiate a Phase 3 clinical study in the U.S. This will be a major milestone for the company and establish an important Catalyst for the shares once initiated.
In this article: BCLI
Read
Oryzon's Pipeline Taking Shape
Monday, March 6, 2017 11:07 AM EDT
Oryzon is focused on developing epigenetic-based therapies and personalized drugs from its proprietary platform technology. Over the past several months, management has made significant progress moving the pipeline forward.
Read
Can-Fite Gearing-Up For Phase 2 NASH Program
Wednesday, March 1, 2017 1:50 PM EDT
Can-Fite's entire market capitalization is only $33 million and I have to believe that the majority of that value is Phase 3 piclidenoson for the treatment of rheumatoid arthritis and psoriasis.
In this article: CANF
Read
Actinium Offers Shareholders Several Interesting Near-Term Catalysts
Friday, February 24, 2017 12:50 PM EDT
Shares of ATNM have performed nicely over the past month, driven by the achievement of several milestones, including the hiring of a new Chief Medical Officer and initiation of a new clinical trial with Actimab-M for multiple ATNM​myeloma.
In this article: ATNM Also: SGEN
Read
Some Quick Thoughts On VistaGen
Wednesday, February 15, 2017 1:04 AM EDT
On February 13, 2017, VistaGen Therapeutics provided a business and financial update following results of the quarter ending December 31, 2016. Here is a quick review of some of the recent happenings at the company.
In this article: VTGN Also: ALKS, ONVO
Read
RedHill Expects Bekinda Top-Line Data In Q2
Monday, February 13, 2017 2:05 PM EDT
RedHill Biopharma Ltd. announced that the final patient has been enrolled in the company's Phase 3 clinical study examining Bekinda as a treatment for acute gastroenteritis and gastritis.
In this article: RDHL
Read
Revive Initiates Bucillamine Phase 2 Study, Expands Focus To Include Cannabinoid Research
Tuesday, February 7, 2017 10:27 AM EDT
Revive Therapeutics would likely improve over the next few years by advancing its pipeline and expanding efforts into cannabinoid research.
In this article: RVVTF
Read
BioSig's Targets Enormous A-Fib Market With Game-Changing Device
Monday, February 6, 2017 10:55 AM EDT
US markets have done well since the election, especially our un-regulated Financials (what could possibly go wrong?), who jumped 18.66% through Friday.
In this article: BSGM
Read
Time To Go Long Brainstorm Cell Therapeutics?
Wednesday, January 18, 2017 10:52 AM EDT
The similarities in strategy and data between Brainstorm, Bluebird and Sarepta are striking. The discrepancies in valuation present an opportunity.
In this article: BCLI, SRPT, BLUE Also: CUR, D-STEM (DEFUNCT)
Read
Immune Pharmaceuticals Is Really Trying Hard
Tuesday, January 17, 2017 2:53 PM EDT
It’s hard to imagine a 21¢ stock with more going on than Immune Pharmaceuticals. The company is really trying in my opinion. There have clearly been past struggles, but I have no issues with the current strategy.
In this article: IMNP
Read
What Does SGEN's Clinical Hold On CD33A Mean For Actinium?
Wednesday, January 4, 2017 5:35 PM EDT
The Seattle Genetic news to temporarily halt clinical work in some studies with CD33A is not a negative reflection on Actinium. It might, in fact, instead be an opportunity.
In this article: SGEN, ATNM
Read
17 to 32 of 54 Posts
<<< 1 2 3 4 >>>